~~<i id='CA741CC56F'><strike id='CA741CC56F'><tt id='CA741CC56F'><pre id='CA741CC56F'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：knowledge 2025-10-01 05:28:48 Page View：7265

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： HIV drugs protect against transmission, even in unprotected sex
Next article： Apple is now the first public company to be valued at $3 trillion

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

App could help diagnose ear infections more accurately — and at home

AUWSchoolofMedicineprofessorpracticesusingtheappandfunneltocheckhisdaughter'sear.DennisWise/Universi

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Ionis drug prevents swelling attacks due to hereditary angioedema

courtesyIonisPharmaceuticalsIonisPharmaceuticals,aCaliforniacompanythatpioneeredawholeclassofRNA-tar